CY1117398T1 - Φαρμακευτικη συνθεση που περιλαμβανει (s)-2-(2-οξοπυρ-ρολιδιν-1-υλο)βουταναμιδιο - Google Patents

Φαρμακευτικη συνθεση που περιλαμβανει (s)-2-(2-οξοπυρ-ρολιδιν-1-υλο)βουταναμιδιο

Info

Publication number
CY1117398T1
CY1117398T1 CY20161100278T CY161100278T CY1117398T1 CY 1117398 T1 CY1117398 T1 CY 1117398T1 CY 20161100278 T CY20161100278 T CY 20161100278T CY 161100278 T CY161100278 T CY 161100278T CY 1117398 T1 CY1117398 T1 CY 1117398T1
Authority
CY
Cyprus
Prior art keywords
butanamide
pharmaceutical composition
oxopyr
rolidin
composition containing
Prior art date
Application number
CY20161100278T
Other languages
English (en)
Inventor
Ioulia Tseti
Original Assignee
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. filed Critical Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Publication of CY1117398T1 publication Critical patent/CY1117398T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία στερεή φαρμακευτική σύνθεση η οποία περιλαμβάνει (S)-2-(2-οξοπυρρολιδιν-1-υλο) βουταναμίδιο, ειδικότερα σε κόκκους που περιλαμβάνουν (S)-2-(2-οξοπυρρολιδιν-1-υλο)βουταναμίδιο και στην παρασκευή αυτών.
CY20161100278T 2011-12-16 2016-04-06 Φαρμακευτικη συνθεση που περιλαμβανει (s)-2-(2-οξοπυρ-ρολιδιν-1-υλο)βουταναμιδιο CY1117398T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11009922 2011-12-16
EP12798303.9A EP2790695B1 (en) 2011-12-16 2012-12-10 Pharmaceutical composition comprising (s)-2-(2-oxopyrrolidin-1-yl)butanamid

Publications (1)

Publication Number Publication Date
CY1117398T1 true CY1117398T1 (el) 2017-04-26

Family

ID=47324162

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100278T CY1117398T1 (el) 2011-12-16 2016-04-06 Φαρμακευτικη συνθεση που περιλαμβανει (s)-2-(2-οξοπυρ-ρολιδιν-1-υλο)βουταναμιδιο

Country Status (11)

Country Link
EP (1) EP2790695B1 (el)
CY (1) CY1117398T1 (el)
DK (1) DK2790695T3 (el)
ES (1) ES2568075T3 (el)
HR (1) HRP20160278T1 (el)
HU (1) HUE026791T2 (el)
PL (1) PL2790695T3 (el)
RS (1) RS54692B1 (el)
SI (1) SI2790695T1 (el)
SM (1) SMT201600096B (el)
WO (1) WO2013087563A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116459225B (zh) * 2023-04-26 2023-11-10 东莞市金美济药业有限公司 一种艾拉戈克钠片及其制备工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0822053A2 (pt) * 2007-12-21 2015-10-20 Alembic Ltd novo revestimento de liberação prolongada das composições farmacêuticas do levitiracetam
WO2009109547A1 (en) 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
US20100172979A1 (en) 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
EP2563340A2 (en) 2010-04-26 2013-03-06 Mahmut Bilgic Water soluble pharmaceutical composition

Also Published As

Publication number Publication date
EP2790695A1 (en) 2014-10-22
SI2790695T1 (sl) 2016-09-30
PL2790695T3 (pl) 2016-07-29
WO2013087563A1 (en) 2013-06-20
RS54692B1 (en) 2016-08-31
HUE026791T2 (en) 2016-07-28
HRP20160278T1 (hr) 2016-05-20
ES2568075T3 (es) 2016-04-27
SMT201600096B (it) 2016-07-01
DK2790695T3 (en) 2016-04-18
EP2790695B1 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1121736T1 (el) Άλατα aramchol
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
GB201106750D0 (en) Novel compounds
BR112014000864A2 (pt) composição de nanocelulose, material de nanocelulose e produto contendo nanocelulose
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
IL232113A (en) Boron-containing compounds, pharmaceuticals containing them and their use in inhibiting arginase
EA201490644A1 (ru) Терапевтические пептиды
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
IL227626A0 (en) A compound of 17-il and γ-ifn inhibitors, preparations containing them and their uses
JO3154B1 (ar) عوامل مضادة لـ trpv4
IL237345A0 (en) Antibody and drug conjugates (adc) that bind to 158p1d7 proteins, preparations containing them and their uses
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12014502856A1 (en) Solid pharmaceutical preparation containing levothyroxine
ITTO20110273A1 (it) Composizione di base per composizione cosmetica oppure farmaceutica.
ATE483720T1 (de) Verbindungen enthaltend organofluorochlorophosphatanionen
BR112014032501A2 (pt) composto, e, composição farmacêutica.
CY1120545T1 (el) Συνθεση για τη θεραπεια της διαταραχης μειωμενης σεξουαλικης επιθυμιας